Recombinant Human Mesothelin (aa 296-580) His Protein, CF

C-Terminal
Catalog # Availability Size / Price Qty
3265-MS-050
Best Seller
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (4)
FAQs
Supplemental Products
Reviews

Recombinant Human Mesothelin (aa 296-580) His Protein, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Recombinant Human CA125/MUC16 (Catalog # 5609-MU) is coated at 2 μg/mL (100 μL/well), the concentration of Recombinant Human Mesothelin C-Terminal (aa 296-580) His-tag that produces 50% of the optimal binding response is found to be approximately 0.5-2.5 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human Mesothelin protein
Glu296-Gly580, with a C-terminal 6-His tag
Accession #
N-terminal Sequence
Analysis
Glu296
Predicted Molecular Mass
33 kDa
SDS-PAGE
40-45 kDa, reducing conditions

Product Datasheets

You must select a language.

x

3265-MS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

3265-MS

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Mesothelin

Mesothelin, also known as CAK1 and ERC, is derived from a 70 kDa precursor that also includes Megakaryocyte Potentiating Factor (MPF) (1-3). The 70 kDa precursor is expressed on the cell surface where it is cleaved at a dibasic proteolytic site to release the 32 kDa glycosylated MPF (3, 4). MPF is a cytokine that potentiates IL-3 induced megakaryocyte colony formation (2, 5). The term Mesothelin refers to the 40 kDa glycosylated protein which remains attached to the cell surface via a GPI linkage. Alternate splicing generates additional Mesothelin isoforms that have either an eight amino acid insertion following Ser408 or a substituted C‑terminal region with no GPI anchor (6). This recombinant human Mesothelin lacks the 8 aa insertion, and within aa 296-580 it shares 59% sequence identity with mouse and rat Mesothelin. Mesothelin is normally expressed on mesothelial cells in the pleura, pericardium, and peritoneum as well as in the developing and postnatal pancreas (1, 7). It is up‑regulated in mesotheliomas and a range of carcinomas and adenomas (8 ‑ 11). Mesothelin promotes tumor cell proliferation, migration, anchorage-independent growth, and tumor progression (10, 12). It is coexpressed with the tumor antigen CA125/MUC16 on advanced ovarian adenocarcinomas and interacts with this molecule to support cell adhesion (13). A soluble form of Mesothelin is released from tumor cells into the serum or tissue effusions (11, 14, 15).

References
  1. Hassan, R. et al. (2004) Clin. Cancer Res. 10:3937.
  2. Kojima, T. et al. (1995) J. Biol. Chem. 270:21984.
  3. Chang, K. and I. Pastan (1996) Proc. Natl. Acad. Sci. 93:136.
  4. Onda, M. et al. (2006) Clin. Cancer Res. 12:4225.
  5. Yamaguchi, N. et al. (1994) J. Biol. Chem. 269:805.
  6. Muminova, Z.E. et al. (2004) BMC Cancer 4:19.
  7. Hou, L.-Q. et al. (2008) Develop. Growth Differ. 50:531.
  8. Ordonez, N.G. (2003) Mod. Pathol. 16:192.
  9. Argani, P. et al. (2001) Clin. Cancer Res. 7:3862.
  10. Li, M. et al. (2008) Mol. Cancer Ther. 7:286.
  11. Scholler, N. et al. (1999) Proc. Natl. Acad. Sci. 96:11531.
  12. Uehara, N. et al. (2008) Mol. Cancer Res. 6:186.
  13. Rump, A. et al. (2004) J. Biol. Chem. 279:9190.
  14. Ho, M. and M.O. Lively (2006) Cancer Epidemiol. Biomarkers Prev. 15:1751.
  15. Robinson, B.W.S. et al. (2003) Lancet 362:1612.
Entrez Gene IDs
10232 (Human); 56047 (Mouse); 60333 (Rat); 102130460 (Cynomolgus Monkey)
Alternate Names
CAK1 antigen; CAK1; megakaryocyte potentiating factor; Mesothelin; MPF; MPFSMRP; MSLN; Pre-pro-megakaryocyte-potentiating factor; SMR; soluble MPF mesothelin related protein

Citations for Recombinant Human Mesothelin (aa 296-580) His Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

4 Citations: Showing 1 - 4
Filter your results:

Filter by:

  1. Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients' Sera
    Authors: A Duran, PE Guerrero, MR Ortiz, D Pérez Del, E Castro, A Garcia-Vel, E Fort, R de Llorens, R Saldova, E Llop, R Peracaula
    Biomedicines, 2022-08-10;10(8):.
    Species: Human
    Sample Types: Control
  2. A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors
    Authors: JK Fierle, J Abram-Sali, V Atsaves, M Brioschi, M de Tiani, P Reichenbac, M Irving, G Coukos, SM Dunn
    Scientific Reports, 2022-01-21;12(1):1136.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer
    Authors: C Montemagno, S Bacot, M Ahmadi, B Kerfelec, D Baty, M Debiossat, A Soubies, P Perret, L Riou, D Fagret, A Broisat, C Ghezzi
    J. Nucl. Med., 2018-03-23;0(0):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  4. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.
    Authors: Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin N, Nguyen M, Jean-Mary G, Tong X, Uppal P, Korochkina S, Forbes B, Chen T, Righi E, Bronson R, Chen H, Orsulic S, Brauns T, LeBlanc P, Scholler N, Dranoff G, Gelfand J, Poznansky M
    J Hematol Oncol, 2014-02-24;7(0):15.
    Applications: Binding Assay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human Mesothelin (aa 296-580) His Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human Mesothelin (aa 296-580) His Protein, CF and earn rewards!

Have you used Recombinant Human Mesothelin (aa 296-580) His Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review